Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure.
This article continues a series of reports summarising recent research developments pertinent to the topic of heart failure. This is a summary of presentations made at scientific sessions of the American Heart Association in November 2000. Clinical studies of particular interest to people caring for patients with heart failure include Val-HeFT, AMIOVIRT and V-MAC. New data from beta-blockers trials are reviewed, highlights from some important developments in post-infarction care, including MIRACL and FLORIDA, discussed and results of some early studies of gene therapy reported.
Thackray
S D
SD
Academic Cardiology, University of Hull, Castle Hill Hospital, Castle Road, HU16 5JQ, Kingston upon Hull, UK.
Witte
K K
KK
Khand
A
A
Dunn
A
A
Clark
A L
AL
Cleland
J G
JG
D000818:Animals; D002986:Clinical Trials as Topic; D017147:Defibrillators, Implantable; D015316:Genetic Therapy; D006333:Heart Failure / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D018482:Muscle, Skeletal / Q000166:cytology